85322-63-0

Basic information

• Product Name: Ethanamine, 2-(2-aminoethoxy)-N,N-dimethyl- (9CI)
• Synonyms: Ethanamine, 2-(2-aminoethoxy)-N,N-dimethyl- (9CI);2-[2-(Dimethylamino)ethoxy]ethanamine 2HCl;2-(2-Dimethylamino-ethoxy)-ethylamine, 98%
• CAS NO: 85322-63-0
• Molecular Formula: C₆H₁₆N₂O
• Molecular Weight: 132.20404
• Product Categories: AMINETERTIARY
• Mol File: 85322-63-0.mol

Chemical Properties

• Boiling Point: 184.738°C at 760 mmHg
• Flash Point: 65.528°C
• Appearance: /
• Density: 0.913g/cm³
• Vapor Pressure: 0.722mmHg at 25°C
• Refractive Index: 1.449
• CAS DataBase Reference: Ethanamine, 2-(2-aminoethoxy)-N,N-dimethyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanamine, 2-(2-aminoethoxy)-N,N-dimethyl- (9CI)(85322-63-0)
• EPA Substance Registry System: Ethanamine, 2-(2-aminoethoxy)-N,N-dimethyl- (9CI)(85322-63-0)

Safety Data

• Hazardous Substances Data: 85322-63-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C6H16N2O/c1-8(2)4-6-9-5-3-7/h3-7H2,1-2H3

Upstream product

• 1704-62-7 1-O-Dimethylaminoethyl-ethylenglykol 

Downstream Products

• 1338346-56-7 2,4-bis(4'-fluorophenethylamino)-6-(2'-(2''-(N,N-dimethylamino)ethoxy)ethylamino)-1,3,5-triazine 

Relevant articles and documents

IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIAL AGENTS

The invention provides novel imidazopyrazine derivatives having the general formula (I), wherein A and R1 to R11 are as described herein formula (I) and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIAL AGENTS

The invention provides novel imidazopyrazine derivatives having the general formula (I), wherein A and R1 to R11 are as described herein NA (I) and pharmaceutically acceptable salts thereof.5 Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS

The invention provides novel imidazopyrazine derivatives having general formula (I), wherein R1 to R11 are as described herein, and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and related diseases.

NOVEL IMIDAZOPYRAZINE DERIVATIVES

The invention provides novel imidazopyrazine derivatives having the general formula (I), wherein A and R1 to R11 are as described herein (I) and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and related diseases.

IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS

The invention provides novel imidazopyrazine derivatives having the general formula (I), wherein A and R1 to R14 are as described herein (I) and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

Method for separating N,N,N'-trimethylbisaminoethylether and/or N,N-dimethylbisaminoethylether from a mixture

The present invention relates to a method for separating N,N,N'-trimethylbisaminoethylether and/or N,N-dimethylbisaminoethylether, from a mixture A comprising N,N,N'-trimethylbisaminoethylether, and N,N-dimethylbisaminoethylether, wherein said method comprises the steps of: (a) contacting said mixture A with an acylating agent, to form a mixture B comprising the amides of N,N,N'-trimethylbisaminoethylether and of N,N-dimethylbisaminoethylether, respectively; and (b1) separating the amide of N,N,N'-trimethylbisaminoethylether from mixture B; and (c1) recovering N,N,N'-trimethylbisaminoethylether from its amide by means of a transamidation reaction; and/or (b2) separating the amide of N,N-dimethylbisaminoethylether from mixture B; and (c2) recovering N,N-dimethylbisaminoethylether from its amide by means of a transamidation reaction.

TETRACYCLIC ANTHRAQUINONE DERIVATIVES

Disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, W, n are defined as in the present application.

Tetracyclic Anthraquinone Derivatives

Disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, W, n are defined as in the present application.

Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof

Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating inflammation are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.

A Method for Separating N,N-Dialkylbisaminoalkylether from Mixtures Comprising N,N-Dialkylbisaminoalkylether and at least one of N,N,N'-Trialkylbisaminoalkylether and N,N,N',N'-Tetraalkylbisaminoalkylether

According to the present invention, a method for separating a primary amine being an N,N- dialkylbisaminoalkylether, from mixtures comprising said primary amine and at least one of a secondary amine being an N,N,N'-trialkylbisaminoalkylether and a tertiary amine being an N,N,N',N'-tetraalkylbisaminoalkylether, comprising the steps: (α) joining said mixture and at least one of a ketone and an aldehyde for reacting said primary amine with said at least one of a ketone and an aldehyde, thereby providing a primary amine based imine by a Schiff base reaction; (β) separating the primary amine based imine from said at least one of the secondary or tertiary amine; and (γ) recovering the primary amine from its primary amine based imine by hydrolysis of the primary amine based imine.